Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc. (PLX): 4 pipeline candidates · ~19 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
19.3 months
D/E 0.52
Lead: Approved
4 candidates
N/A
N/A
A transparent, data-derived signal for Protalix BioTherapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$167.2M
Cash
$41.0M
Quarterly Burn
$8.5M
Runway
19.3 mo
Revenue
$33.8M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
99
Total value held
$35.9M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 3,616,962 | $7.8M |
| mak capital one llc | 3,544,139 | $7.7M |
| renaissance technologies llc | 1,224,800 | $2.7M |
| state street corp | 972,815 | $2.1M |
| northern trust corp | 885,448 | $1.9M |
| geode capital management, llc | 865,298 | $1.9M |
| stratos wealth partners, ltd. | 500,000 | $1.1M |
| vanguard portfolio management llc | 432,485 | $938K |
| prospera financial services inc | 418,570 | $908K |
| morgan stanley | 301,793 | $655K |
Showing top 10 of 99 institutional holders of Protalix BioTherapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Protalix BioTherapeutics, Inc.'s pipeline?
Protalix BioTherapeutics, Inc. (PLX) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Protalix BioTherapeutics, Inc.'s lead drug candidate?
Protalix BioTherapeutics, Inc.'s most advanced tracked candidate is elelyso (Approved) for Gaucher disease.
What is Protalix BioTherapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Protalix BioTherapeutics, Inc. has approximately 19.3 months of cash runway.
What is Protalix BioTherapeutics, Inc.'s market capitalization?
Protalix BioTherapeutics, Inc.'s market capitalization is approximately $167.2M.
Who is the CEO of Protalix BioTherapeutics, Inc.?
Mr. Dror Bashan is the chief executive officer of Protalix BioTherapeutics, Inc. (PLX).
Get the full picture on Protalix BioTherapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.